we administered recombinant human granulocyte colony-stimulating factor ( rhg-csf ) to four patients with myelodysplastic syndrome ( mds ) and three patients with non-mds ( two malignant lymphoma and one lung cancer ) as a part of a phase ii trial and analyzed the effects of rhg-csf on the neoplastic cells of mds by performing sequential chromosome analyses on the bone marrow cells .
C0024299
malignant lymphoma
C0597032
neoplastic cells